loader2
Login Open ICICI 3-in-1 Account
Open ICICI 3-in-1 Account

Neogen Chemicals Results: Latest Quarterly Results & Analysis

Open Free Trading Account Online with ICICIDIRECT
+91
Neogen Chemicals Ltd. 04 Aug 2025 12:13 PM
Result PDF

Q1FY26 Quarterly Result Announced for Neogen Chemicals Ltd.

Specialty Chemicals company Neogen Chemicals announced Q1FY26 results

  • Revenues stood at Rs 187 crore, higher by 4% YoY.
  • EBITDA for Q1FY26 is Rs 32 crore, higher by 2% YoY.
  • EBITDA Margin stood at 16.9%.
  • Profit after tax for Q1FY26 stood at Rs 10 crore. PAT largely mirrored operational performance.
  • Earnings per share (EPS) for Q1FY26 stood at Rs 3.89 per share (Rs 4.35 per share in Q1FY25) not annualised.

Haridas Kanani, Chairman & Managing Director, Neogen Chemicals said: "We delivered a resilient performance in Q1FY26, demonstrating the inherent strength of our diversified business model, even with our Dahej plant unavailable for the entire quarter due to the unfortunate fire. Volume-driven growth was propelled by our base business.

Additionally, Neogen Ionics began contributing by initiating Commercial Sales in both Electrolyte and Lithium Electrolyte Salts. Despite the prevailing soft pricing environment, we effectively maintained our performance showcasing the strength and agility of our business model.

Our strategic initiatives are moving forward with good momentum, as is our recovery from the fire incident. We have secured initial insurance claims and the rebuilding of our Dahej plant is progressing swiftly aiming for completion by next year. Concurrently, our greenfield facility at Pakhajan for Electrolyte and Lithium Salts is taking shape, with key milestones accomplished and vital equipment ordered. This project is a cornerstone of our future growth.

Looking ahead, our vision for Neogen Chemicals remains ambitious and clearly defined. The proposed JV with Morita is a testament to our long-term strategy, firmly positioning us in the rapidly growing battery chemicals sector. While we have adjusted our near-term revenue guidance to reflect current operational realities, our long-term trajectory is robust. We are confidently building a stronger, more diversified Company, ready to capitalize on future opportunities.”

Result PDF

Result PDF

Specialty Chemicals company Neogen Chemicals announced Q4FY25 & FY25 results

Q4FY25 Financial Highlights:

  • Revenues stood at Rs 203 crore, reflecting a YoY growth of 2%.
  • EBITDA came in at Rs 36 crore, marking a 2% increase compared to the previous year.
  • Profit Before Tax (PBT) was Rs 18 crore, showing a decline of 21% YoY.
  • Adjusted Profit Before Tax amounted to Rs 4 crore, representing a sharp drop of 84% YoY.
  • Profit After Tax (PAT) stood at Rs 2 crore, down by 86% YoY.

FY25 Financial Highlights:

  • Revenues were Rs 778 crore, reflecting a YoY growth of 13%.
  • EBITDA amounted to Rs 136 crore, up by 24% YoY.
  • Profit Before Tax (PBT) was Rs 64 crore, showing an increase of 22% YoY.
  • Adjusted Profit Before Tax stood at Rs 50 crore, marking a decline of 5% YoY.
  • Profit After Tax (PAT) came in at Rs 35 crore, down by 2% YoY.

Commenting on the Q4FY25 performance, Haridas Kanani, Chairman & Managing Director, Neogen Chemicals said: "We have closed FY25 on a strong note, achieving 13% revenue growth & 24% improvement in EBITDA. We accomplished this against a difficult & challenging global industry backdrop. This led to weak pricing, despite some pockets of domestic demand resilience. In addition, our Dahej plant was not fully operational towards the end of Q4 due to the fire incident. Our solid performance was a result of our ability to swiftly adapt to a challenging environment by strategically pivoting towards product applications that had favorable demand.

Concerning the recent fire incident at our Dahej plant, I would like to reassure all our stakeholders that this is just a temporary setback. With our dedicated team and unwavering resolve, we are confident we will not only overcome the setback but emerge stronger and more efficient. In fact, we have already begun construction of another plant at an adjacent location at the same site which will replace the existing plant.

We are making strong progress on the Neogen Ionics' Lithium Salts and Electrolytes project. As several domestic battery manufacturers are set to commence production in FY26, boosting demand for battery materials, we are also on track to commission, by the end of FY26, our greenfield Battery Materials facility, using MUIS technology.

While FY25 was a challenging year, the road ahead looks promising. Neogen Chemicals is well poised to leverage its expertise across multiple chemistries to drive sustained growth going forward. In addition to actively focusing on higher-value specialty chemicals, significant contribution from upcoming lithium-ion battery materials segment will further diversify our revenue streams and accelerate our growth trajectory.”

Result PDF

Specialty Chemicals company Neogen Chemicals announced Q3FY25 results

  • Revenues: Rs . 201.4 crore during Q3FY25, change 22% YoY.
  • EBITDA: Rs 34.6 crore during Q3FY25, change 71% YoY.
  • PBT: Rs 15.3 crore during Q3FY25, change 263% YoY.
  • PAT: Rs 10 crore during Q3FY25, change 844% YoY.

Haridas Kanani, Chairman & Managing Director, Neogen Chemicals, said: “Our Q3FY25 results demonstrate a robust recovery, with revenue up 22% and EBITDA up 71%. This growth is attributed to strong ramp-up in BuLi Chem and sustained growth in the base business volumes. Higher topline was achieved despite lower RM prices and resultant realizations acrossseveral product categories. New product launches and the pursuit of export opportunities drove the robust recovery. To mitigate the persistent slowdown in agrochemicals, we have strategically created additional end-use sectors such as semiconductors, flavors & fragrances and select industrial CSM opportunities. This highlights the adaptability of our agile business model, enabling us to meet evolving market needs and capitalize on emerging opportunities.

Neogen Ionics is rapidly advancing its Lithium Salts and Electrolyte projects. A major ACC battery manufacturer has already started trial production plant in India, with several others preparing to do so within the next two years. This will drive their demand for local procurement of both Electrolyte and Lithium Salt. Meanwhile, we are supplying products from our initial capacity to potential manufacturers, aiming to establish long-term customer partnerships. We are on schedule to commission our greenfield Battery Materials facility in the second half of FY26. This facility, using MUIS technology, is taking shape with majority of erection and engineering works now complete. The modular construction process is proceeding with equipment assembly and installation.

Overall, we are confident of achieving FY26 revenue guidance of Rs 950-1,000 crore in the standalone business. Beyond FY26, the rapid scale up in Neogen Ionics will drive consolidated performance. We maintain a long-term growth strategy, undeterred by short-term setbacks. Neogen Chemicals remains committed to capitalizing on emerging opportunities to generate sustained value for all stakeholders.”

Result PDF

Specialty Chemicals company Neogen Chemicals announced Q2FY25 results

  • In Q2FY25, revenue was higher by 20% to Rs 193 crore fueled by increased volumes in the core business, coupled with incremental contribution from BuLi Chem.
  • EBITDA stood at Rs 35 crore, an increase of 33% YoY.
  • Profit after Tax (PAT) grew by 38% to Rs 11 crore.
  • Earnings per share (EPS) for Q2FY25 stood at Rs 4.15 per share (Rs. 3.17 per share in Q2FY24).

Haridas Kanani, Chairman & Managing Director, Neogen Chemicals, said: “We have delivered a strong performance during the period under review amid a challenging backdrop of events marked by soft demand, oversupply situation, geopolitical tensions and inflationary pressures, which have eroded industry’s pricing power and profitability. Our 20% revenue improvement and 38% PAT growth in Q2FY25 is a testament to our team's unwavering dedication, adaptability, and ability to navigate challenging market conditions. Volume gains in the base business as well as contributions from BuLi Chem and Neogen Ionics fostered consolidated performance.

Through Neogen Ionics, we are making deep inroads in the Battery Materials business. Through our collaborative efforts, we have developed and exchanged multiple recipes of Electrolyte & Lithium Salt combinations with our customers. While doing so, we have gained valuable insightsinto the technological capabilities and market expertise. Our pilot production lines are currently manufacturing and shipping commercial trial lots, while the initial commercial production facilities are operational and fulfilling early market demand. Stringent quality standards are being maintained through strict adherence to safety protocols. The construction of our dedicated greenfield Battery Materials plant in Dahej using MUIS technology license is advancing steadily & remains on expected timelines. We are strategically phasing the commissioning process aligning with Battery capacities coming in India.

While we anticipate a potential demand recovery later in FY25, we are committed to investing in our long-term growth strategy to secure our future. In the face of global economic uncertainty, we at Neogen Chemicals are adapting to changing conditions, and remain steadfast in our commitment to growth, innovation, and delivering value to ourstakeholders.”

Result PDF

Speciality Chemicals company Neogen Chemicals announced Q1FY25 results:

  • In Q1FY25, revenue was higher by 9% to Rs 180.0 crore despite challenging operating scenario.
  • EBITDA stood at Rs 30.8 crore, an increase of 10% YoY. This improved despite higher employee costs and other expenses, in-line with capacity build up efforts in Neogen Ionics.
  • Margins were maintained at 17.1% YoY led by operational efficiencies, even as pricing pressures continued across key products.
  • Profit after Tax (PAT) grew by 18% to Rs 11.5 crore. PAT performance reflects the strong operating trend, further boosted by lower tax rate. Depreciation and interest expenses are expected to rise with accelerated CAPEX trajectory in Battery Chemicals.
  • Earnings per share (EPS) for Q1FY25 stood at Rs 4.35 per share (Rs. 3.92 per share in Q1FY24).

Commenting on the Q1FY25 performance, Haridas Kanani, Chairman & Managing Director, Neogen Chemicals said: “We are pleased to report 9% revenue growth and 18% PAT improvement this quarter. This was driven by gradual demand recovery with better volumes amid soft pricing. Effective supply chain management amidst logistical challenges strengthened customer relationships. Both BuLi Chem and Neogen Ionics contributed positively to the overall consolidated performance.

Our growth initiatives are on track, with initial capacities for Lithium Electrolyte Salts and Electrolytes now operational. We are shipping Lithium Saltsto global customers commercially, while Electrolytes are in trial production with commercial quantities aligned with upcoming cell production capacities in India. These efforts provide valuable market insights for our upcoming greenfield plant using MUIS technology, where construction has commenced. I am glad to share that we are one of the first companies in India whose Electrolyte supplied from the commercial plant is meeting global standards. We are proud to support India’s efforts for self-reliance in Lithium-ion battery manufacturing.

To mitigate current agchem market challenges in the existing business, we are looking at nonagchem opportunities until the global agchem market recovers and remain confident of achieving Rs 900-1,000 crore in revenues in FY26 based on anticipated recovery in the later half of this financial year.

We are steadily recovering from the ongoing macro challenges and anticipate stronger growth going ahead. Notwithstanding the current operating environment, we believe that Indian chemical industry is on the cusp of exponential growth in the long run. Neogen Chemicals will pursue all avenues to outperform and create enduring value for its stakeholders.”

Result PDF

Speciality Chemicals company Neogen Chemicals announced Q4FY24 & FY24 results:

Q4FY24 Financial Highlights:

  • Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA): EBITDA increased by 10% to Rs 36 crore.
  • Profit Before Tax (PBT): PBT saw a growth of 8% reaching Rs 22 crore.
  • Profit After Tax (PAT): PAT grew by 18%, amounting to Rs 17 crore.
  • Earnings Per Share (EPS): EPS stood at Rs 6.42 per share, compared to Rs 5.74 per share in Q4FY23.

FY24 Financial Highlights:

  • Revenue remained at Rs 691 crore despite a significant decrease in raw material prices.
  • Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA): EBITDA stood at Rs 110 crore, marginally down by 1% with an EBITDA Margin of 16%.
  • Profit Before Tax (PBT): PBT experienced a decrease of 26%, concluding at Rs 53 crore.
  • Profit After Tax (PAT): PAT was down by 29%, ending the year at Rs 36 crore.

Commenting on the Q4FY24 performance, Haridas Kanani, Chairman & Managing Director, Neogen Chemicals said, “Financial Year 2024 marked a significant milestone for Neogen Chemicals as we embarked on an accelerated growth trajectory, establishing a robust foundation to fuel India’s growing EV ecosystem. Strategic initiatives undertaken during the year such as acquisition of BuLi Chem, licensing agreement with MUIS, equity raise through preferential route and land acquisition by Neogen Ionics, were all aligned to position us for the future and accelerate our growth agenda. I want to express my appreciation to the entire Neogen family for their commitment and dedicated efforts to our shared goal and being part of this dynamic journey.

Our performance during the year mirrors the persistent global challenges experienced by industry, which had a detrimental effect on demand. This includes cheap dumping in India, inventory adjustments, military escalations, and logistical crisis, among others Our adaptable business model and manufacturing prowess enabled us to navigate through these obstacles and deliver a resilient performance.

We are making considerable progress in establishing our greenfield Battery Materials project. The plant design using MUIS, Japan technology has already been finalised and we have started issuing the PO’s. Construction work is expected to commence shortly, as we stay on track to commission this facility by H2 of FY2026. Once operational, it will position us as an important partner for EV battery manufacturers in the country. In the interim, we are building initial commercial capacities for both Electrolytes and Lithium Electrolyte Salts for immediate needs of the customers I am happy to share that we have started shipping small batches of Lithium Electrolyte Salts to global customers and Electrolytes to local customers, and the feedback regarding quality and efficacy has been positive.

Despite several macro challenges in the previous year, we foresee the present year to be more promising, considering the current pace of recovery. Our overarching goal is to capitalize on our fundamental strengths across multiple chemistries to consistently enhance value for all our stakeholders”

Result PDF

Neogen Chemicals announced Q2FY24 results:

  • In Q2FY24, revenue was Rs 161.7 crore, with a growth of 9% YoY. This was achieved despite the challenging external environment aggravated by global inventory destocking, the slowdown in key export markets, and geopolitical uncertainties among others. Recent capacity expansions, stable demand, and contributions from BuLi Chem supported the growth momentum.
  • EBITDA at Rs 25.9 crore was higher by 7% YoY. Growth in profitability was reflected by an improved product mix and a reduction in key input and RM costs.
  • Profit after tax (PAT) stood at Rs 7.9 crore, lower by 20% YoY compared to Rs 9.9 crore in Q2FY23. PAT was lower due to higher finance costs and depreciation related to ongoing CAPEX initiatives undertaken by the Company.
  • Strategic debt repayment from recent preference share proceeds will help lower the finance expenses in the near term.
  • Earnings per share (EPS) for Q2FY24 stood at Rs 3.17 per share (Rs. 3.95 per share in Q2FY23).

Commenting on the Q2FY24 performance, Haridas Kanani, Chairman & Managing Director, Neogen Chemicals said, “I am pleased to share that we have maintained a consistent performance despite persistent external headwinds that have adversely impacted the end-user demand. We achieved a 9% growth in revenues along with a 7% improvement in EBITDA on a YoY basis. Positive contributions from recently acquired BuLi Chem, rationalisation of key RM & input costs, along with efficient inventory management were notable drivers of performance during the quarter.

In a significant development, we recently raised ~Rs 253 crore through preferential allotment to leading institutional investors. I would like to express my appreciation for the trust placed in us and the support extended toward our future growth endeavors. We will carefully deploy these funds to establish a strong presence in the Battery Materials space while sustaining the growth momentum in the existing business.

We are rapidly progressing along the outlined growth path. BuLi Chem has started contributing and also achieved break-even. This will further ramp up as we move along. The contribution from value-added products is also increasing, and our endeavor is to add more complex products by leveraging our R&D expertise and manufacturing capabilities. Our efforts related to Battery Materials are advancing successfully. Our project using MUIS technology is evolving positively, and we are on schedule to finalize the design work by the end of this year. Our interactions with key customers for both Lithium Electrolyte Salts and Electrolytes are making good progress, and we are seeing strong interest from international customers, especially for Electrolyte Salts. We are confident of garnering a significant share as the transition to EVs gains momentum.

Overall, we are well poised to capitalize on the upcoming opportunities. Building upon the solid foundation, we remain steadfast in our pursuit to not only elevate our performance momentum but also consistently enhance value for our stakeholders.”

Result PDF

Specialty Chemicals company Neogen Chemicals announced FY23 results:

  • In FY23, revenues were at Rs 686.2 crore, with a growth of 41% YoY
  • EBITDA at Rs 111.6 crore in FY23 was higher by 29% on account of a positive mix change in the business
  • Profit after tax (PAT) stood at Rs 50.0 crore during FY23, higher by 12% compared to Rs 44.6 crore in FY22
  • Earnings per share (EPS) for FY23 stood at Rs 20.03 per share (Rs. 18.70 per share in FY22)
  • The Board has recommended a final dividend of Rs 3 per equity share for FY23 (Rs. 2.75 per equity share in FY22) subject to the approval of the shareholders
  • Collective CAPEX for all the new projects is ~Rs 450 crore
  • Debt to Equity will continue to remain below 1.25x

Commenting on the Q4FY23 & FY23 performance, Haridas Kanani, Chairman & Managing Director, Neogen Chemicals said: “I am happy to share that we have concluded the year on a strong note despite challenging operating scenario aggravated by continued volatility in input costs, disruption of global supply chains due to Russia Ukraine conflict and variations in foreign exchange rates among others. Amid all these headwinds, we demonstrated solid financial performance in FY23 steered by 41% growth in revenues and 29% expansion in EBITDA. More importantly, we reported the Highest-Ever revenues and PAT in the Company’s history propelled by a positive demand environment, the onset of several expansion initiatives, and the augmentation of the product portfolio. This is a testament of our commitment and perseverance towards building a solid foundation for the future.

FY23 was a momentous year for Neogen Chemicals as we charted ambitious growth plans for both existing as well as Battery Chemicals business and saw a lot of these initiatives take concrete shape. On one hand, we acquired 100% stake in BuLi Chemicals India Private Limited (“Buli Chem”) to strengthen our product offerings while on the other hand, we signed a landmark agreement with MUIS, Japan to acquire a manufacturing technology license for electrolytes in India. Both these events will significantly bolster our competitive position in the market and lay the roadmap for the future. We have markedly expanded our R&D prowess across several high-potential chemistries to offer deep value to our customers. Initiatives under the Battery Chemicals business are progressing well, and we are on track to achieve several milestones as per our internal forecasts.

The roadmap appears equally encouraging and we are ready to march to the next leg of growth that will demonstrate our manufacturing capabilities at scale as well as expertise in several complex chemistries. The industry is supportive, and the demand scenario continues to be favourable. Our objective is to continue on this profitable growth journey and deliver sustained value for our stakeholders.”

 

 

Result PDF

Neogen Chemicals announced Q3FY23 results:

  • Q3FY23 & 9MFY23:
    • Neogen Chemicals Limited (Neogen) reported strong financial performance during the quarter and nine months ended Q3FY23. In 9MFY23, the company delivered 46% growth in revenues, 32% increase in EBITDA and 23% growth in Profit After Tax (PAT).
    • In 9MFY23, revenues were at Rs 482.3 crore, with a growth of 46% YoY. Growth was strengthened by increased utilization of plants, driven by stable demand from key end-user industries. Efforts to expand the high-margin advanced intermediates and custom synthesis manufacturing business have begun to show positive results.
    • EBITDA at Rs 79 crore in 9MFY23 was up 32% in spite of the ongoing inflation in certain raw materials and utilities, strong EBITDA results were achieved through favorable management of product mix. The company experienced an increase in certain costs such as employee expenses, etc., consistent with management's plan to expand the workforce across departments.
    • The company delivered a healthy EBITDA performance mainly because it was able to pass on the significant cost increase in the prices of lithium raw materials to customers. As a result, the absolute EBITDA remained protected.
    • Profit after tax (PAT) stood at Rs 35.7 crore during 9MFY23, higher by 23% compared to Rs 29 crore in 9MFY22. The growth in PAT reflected the operational performance, moderately affected by high depreciation associated with new capacity additions and an increase in finance costs due to elevated interest rates.
    • Earnings per share (EPS) for 9MFY23 stood at Rs 14.29 per share (Rs 12.43 per share in 9MFY22).

Commenting on the Q3 & 9MFY23 performance, Mr. Haridas Kanani, Chairman & Managing Director, Neogen Chemicals said: “We registered solid performance trajectory in Q3FY23, bolstered by 40% YoY gains in revenue with healthy profitability, where both EBITDA and PAT increased by 27% and 40% YoY respectively. Our performance has been consistent, and we are witnessing accelerated built up in our business based on strong visibility and continued positive demand environment. Our capabilities in chosen chemistries are exceptional and well appreciated by our partner customers. In-line with our focus on high value-addition, we are scaling up revenues across both advanced intermediates and custom synthesis manufacturing as reflected in better profitability trends. This was achieved despite impact of continued high inflation in some input and utility costs during the period under review

Our expansion plans are ambitious, but modular in nature. Our intent is to cement our leadership position in the existing business, while garnering substantial market share in the high potential Lithium-ion battery chemicals space. All the strategic initiatives undertaken this quarter including new CAPEX announcements and forming a separate entity for battery chemicals business are steps in the right direction to gain early mover advantage, be future ready with capacities meeting demand and strengthening our technological expertise. All this will result in sustained valuecreation for our stakeholders. With this, I believe we have built a solid foundation for Neogen Chemicals to independently grow and self-sustain both its existing as well as battery chemicals businesses.

I am optimistic that these advancements will enable Neogen to achieve quantum leap in its earnings and demonstrate its manufacturing excellence to customers across the globe. A favourable demand outlook and India's emergence as a favored manufacturing hub will expand the market size and draw in additional customers along the value chain.”

Result PDF

Specialty chemical firm Neogen Chemicals announced Q2FY23 results:

  • Neogen Chemicals Limited (Neogen) remained on a high growth trajectory during Q2FY23 and H1FY23. The company delivered 50% growth in revenues, 35% improvement in EBITDA and a 13% increase in Profit After Tax (PAT)
  • At Rs 296 crore, revenues registered a growth of 50% in H1FY23, over H1FY22 revenue of Rs 197.8 crore
  • EBITDA at Rs 48.9 crore in H1FY23 was up 35% despite inflationary cost pressures in key raw materials and utilities
  • The EBITDA percentage margin considers the impact of higher revenues and higher RM costs with preserved absolute earnings. Profit after tax (PAT) stood at Rs 21.0 crore during H1FY23 as compared to Rs 18.5 crore in H1FY22
  • Earnings per share (EPS) for H1FY23 stood at Rs 8.41 per share (Rs 7.94 per share in H1FY22)

Commenting on the Q2 & H1 FY23 performance, Haridas Kanani, Chairman & Managing Director, Neogen Chemicals, said: “We have reported superior performance during the first half of fiscal year 2023, reflected by 50% growth in revenues, 35% improvement in EBITDA and 13% increase in Profit After Tax. This is an outcome of collective efforts put in by our teams to ensure that we expand our capabilities to the fullest and offer best possible value to our long-standing customers. The performance was fueled by continued positive demand outlook from key end-user segments, further aided by gains from incremental capacity available over same period last year. All this was achieved in an environment that was premised on prolonged inflationary headwinds in key raw materials and other utilities.

Our CAPEX initiatives are underway, and construction is progressing as expected both in lithium-ion battery chemicals and existing business operations. We aim to make significant inroads in the chosen products and chemistries to elevate our performance trajectory. We have been in constant dialogue with our customers and have received positive feedback for our products. Sizeable CAPEX plans will be lined up in the second half of current fiscal year, based on how final discussion progresses for lithium-ion battery materials space. Within CSM and Advanced Intermediate space, we remain confident of garnering additional share based on our in-house strengths and capabilities across several chemistries. The objective is to diversify the product mix towards value-added offerings, and we are on the right track to attain that.

The medium-to-long term prospects look favorable and Neogen is well poised to drive higher topline and profitability based on strong execution abilities. This is in addition to benefits emerging from upcoming projects that will start contributing from next year. The demand landscape remains promising and Neogen will channelise its experience to deliver sustained performance in the years to come.”

Result PDF

Trending News

Saregama India's announced strategic partnership with, and investment in, Sanjay Leela Bhansali's Bhansali Productions

Saregama India's announced strategic partnership with, and investment in, Sanjay Leela Bhansali's Bhansali Productions

Published on 17-Dec-2025 09:01

The Competition Commission of India (CCI) has approved ITC’s acquisition of the paper and pulp manufacturing business of Aditya Birla Real Estate Ltd (ABREL).

The Competition Commission of India (CCI) has approved ITC’s acquisition of the paper and pulp manufacturing business of Aditya Birla Real Estate Ltd (ABREL)

Published on 17-Dec-2025 09:00

Zydus Lifesciences has received a USFDA acceptance for its ANDA of for copper histidinate (CUTX-101), intended to treat Menkes disease in pediatric patients.

Zydus Lifesciences has received a USFDA acceptance for its ANDA of for copper histidinate (CUTX-101), intended to treat Menkes disease in pediatric patients.

Published on 16-Dec-2025 09:05

KIMS has commenced operations at its newly established hospital located at the PES University campus in Electronic City, Bengaluru

Krishna Institute of Medical Sciences (KIMS) has commenced operations at its newly established hospital located at the PES University campus in Electronic City, Bengaluru

Published on 16-Dec-2025 09:03

Power Grid Corporation of India Ltd (POWERGRID) has been declared the successful bidder under Tariff-Based Competitive Bidding

Power Grid Corporation of India Ltd (POWERGRID) has been declared the successful bidder under Tariff-Based Competitive Bidding 

Published on 16-Dec-2025 09:01

Marico is in talks to acquire Cosmix, a startup that sells plant-based protein supplements

Marico is in talks to acquire Cosmix, a startup that sells plant-based protein supplements

Published on 16-Dec-2025 09:00

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Play Store App Store
market app
✕
Application status